This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
JAK kinases are now well-established targets in immunology, but the class has always had safety concerns hanging over it. The…
molecule
1 year ago ●
2 mins read
Kinase inhibitors are increasingly being explored for diseases beyond cancer. While SGK1 has been a cancer target, SGK1 has also…
molecule
1 year ago ●
1 min read
Vanin-1 is a biotinidase (nitrilase superfamily) that hydrolyzes pantetheine. Despite the critical role of pantetheine, vanin-1 deficient mice don’t appear…
molecule
1 year ago ●
2 mins read
LRRK2 is a target of interest for Parkinson’s disease (e.g. DNL-151), but development had been slowed by concerns about potential…
molecule
1 year ago ●
1 min read
“Compound 25,” inhibits HPK1 via a rare “P-loop folded” active site conformation. The molecule was nominated by reviewer Julien Lefranc,…
molecule
1 year ago ●
1 min read
1. This month’s cover molecule, Pfizer’s PF-07321332 (API of Paxlovid) is an oral, reversible covalent SARS-CoV-2 main protease inhibitor, which has been…
molecule
1 year ago ●
2 mins read
Load More
